1

1 2 3	Title: Effects of chemotherapy on skeletal muscle mitochondrial oxidative capacity using Near-Infrared Spectroscopy (NIRS): Protocol paper for an observational mixed model repeated measures design in patients with breast and gynecological cancer
4	Evaluation of mitochondrial oxidative capacity during chemotherapy using NIRS
5	
6 7 8 9 10 11	Funding: This study was partially funded through the Prisma Health Cancer Institute Office of Philanthropy and Partnership and the University of South Carolina School of Medicine Greenville Summer Scholars Program. Funders played no role in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities.
12	
13	Competing Interests: The authors have declared no competing interests.
14	
15 16	Data availability: All relevant data resulting from protocol execution of this study will be made available upon study completion.
17 18	
19 20	Randolph Hutchison ¹ , Shannon Smith ² , Chloe Caudell ² , Sara Biddle ³ , W. Larry Gluck ³ , Jennifer Trilk ^{2*}
21 22	
23 24 25 26 27	 Department of Health Sciences, Furman University, Greenville, South Carolina, United States of America Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, South Carolina, United States of America Cancer Institute, Prisma Health, Greenville, South Carolina, United States of America
28	
29	*Corresponding Author
30	

It is made available under a CC-BY 4.0 International license .

31 Corresponding Author Email: trilk@greenvillemed.sc.edu

32

33 Abstract

34

35 Chemotherapy-associated cachexia results in significant metabolic disturbances and loss 36 of skeletal muscle. These physiologic effects increase fatigue, reduce physical functioning, and 37 decrease quality of life in patients undergoing treatment for cancer. Mitochondrial dysfunction, a 38 hallmark of metabolic disturbances in the skeletal muscle, has previously been studied in health 39 participants using invasive muscle biopsy and/or time consuming, high-cost magnetic resonance 40 spectroscopy. However, less is understood regarding mitochondrial dysfunction in patients with 41 cancer. Near infrared spectroscopy (NIRS) is a non-invasive and cost-effective approach to 42 assessing mitochondrial function of skeletal muscle by measuring oxygenated and deoxygenated 43 hemoglobin and calculating the resulting tissue saturation index. NIRS has not vet been utilized 44 to evaluate skeletal muscle change in cancer patients throughout chemotherapy. Therefore, we 45 plan to conduct a single center clinical trial, using an observational mixed model repeated 46 measures design to evaluate the change in mitochondrial oxidative capacity from baseline and 47 throughout progression of an oncologist-prescribed chemotherapy regimen. Evaluation of 48 mitochondrial function will be performed by taking real-time. NIRS in-situ measurements within 49 the working muscle during stationary cycling exercise and subsequent recovery periods (e.g. 50 "on" kinetics and "off" kinetics). We also plan to observe if there is a difference in mitochondrial 51 oxidative capacity between different chemotherapy regimens across different patients. This pilot

It is made available under a CC-BY 4.0 International license .

- 52 study will provide information on the feasibility of capturing on/off kinetics mitochondrial
- 53 function data longitudinally using NIRS in patients newly diagnosed with breast or
- 54 gynecological cancer, provide preliminary data for future extramural funding, as well as inform
- 55 the scientific community of results through dissemination via conferences and peer-reviewed
- 56 publications.

It is made available under a CC-BY 4.0 International license .

4

69

70 Introduction

71 In the United States, more than 3.8 million women are currently receiving chemotherapy 72 treatment, or have completed treatment, for breast or gynecological cancer [1]. Fortunately, over 73 the past 25 years, the ability to detect and treat cancer has allowed breast cancer 5-year survivor 74 rates to increase to 85 [1], ovarian cancer 5-year survivor rates to increase to 49% [2], and 75 uterine cancer 5-year survivor rates to increase to 81% [3]. Unfortunately, while chemotherapy 76 has improved survival rates amongst patients with breast and gynecological cancer, side effects 77 include unfavorable body composition changes [4], increases in fatigue [5], reductions in 78 physical functioning [6], and decreased quality of life (QOL) [7]. Most of these symptoms are 79 due to chemotherapy-induced muscle wasting, also known as cachexia [8–10]. According to the 80 National Cancer Institute, cachexia is estimated to occur in up to 80% of people with advanced 81 cancer [8,11] and involves reduced size and content of mitochondria [12,13] and subsequent 82 deterioration of mitochondrial function and its oxidative capacity associated with reduced energy 83 production for physical functioning [9,10,14]. Cachexia has negative implications for patients 84 with breast and gynecologic cancer; therefore, the increase in survivorship has been an increase 85 in focus on understanding mechanisms of cachexia, such as mitochondrial dysfunction, with the 86 aim of studying these mechanisms to understand how to improve quality of life for [10].

87 Previous studies have relied on more invasive tools to assess pathological progression of
88 mitochondrial [15,16]. Muscle biopsies have been the gold standard assessment but cause

It is made available under a CC-BY 4.0 International license .

5

89 significant discomfort to the patient and may not represent *in vivo* activation of the skeletal 90 working muscle tissue associated with [17]. Magnetic Resonance Spectroscopy (MRS) provides 91 in vivo measurements but is cost prohibitive, time intensive, requires technical expertise, and 92 competes with other clinical needs within the [17]. Metabolic ventilatory measures have been 93 established as a gold standard in evaluation of pathophysiology with many chronic diseases 94 except for large scale studies in cancer chemotherapy treatment [18–20]. These measurements 95 could provide critical mechanistic understanding of oxygen delivery and utilization from a 96 systematic whole-body approach [21]. To understand local skeletal muscle oxygen uptake 97 kinetics, Near Infrared Spectroscopy (NIRS) has been validated with muscle biopsies and 98 [22,23], as a low cost, non-invasive alternative assessing mitochondrial capacity in clinical [17]. 99 NIRS measurement of tissue oxygenation has been well studied and a thorough background on 100 NIRS can be found elsewhere [17,22,24,25]. Briefly, biological tissue has a relatively good 101 transparency for light in the near infrared region (700-1300 nm) and transmits photons through 102 organs for *in situ* monitoring. The refracted light is converted into grams of oxyhemoglobin 103 (O₂Hb) and deoxyhemoglobin (HHb) based on the modified Beer-Lambert law[26]. NIRS 104 devices with multiple transmitters at different distances from the receiver can calculate the 105 Tissue Saturation Index (TSI)= $O_2Hb/(O_2Hb + HHb)$ and reflects the percentage of measured 106 blood that is oxygenated.

Assessment of mitochondrial capacity with NIRS includes studies of clinical populations with peripheral artery [27], chronic kidney [24], and neurologic diseases such as traumatic spinal cord injury and multiple [22], as well as comparisons with healthy [28] and assessment of agerelated differences in skeletal muscle oxidative [17]. However, there is a dearth of NIRS studies

It is made available under a CC-BY 4.0 International license .

6

111 examining the effects of chemotherapy on skeletal muscle mitochondrial function in patients 112 with cancer. Only two studies to our knowledge have utilized NIRS to measure muscle 113 oxygenation variables in cancer survivors. Ederer, et al. [29] determined that [HHb] and 114 [Hb]total were significantly lower in eight cancer survivors (all eight received chemotherapy and 115 five received radiation) compared to healthy controls during exercise at ventilatory threshold. 116 Grigoriadis, et al., [30] did not find a significant difference in muscle oxygenation variables 117 between 23 patients with breast cancer (16 received chemotherapy, nineteen received radiation 118 therapy, and 21 received hormonal therapy) and 23 participants who served as age and BMI 119 matched controls. Recent literature of near infrared spectroscopy related to cancer primarily 120 involves detection and identification of cancerous [31] or the use of near infrared light as a 121 photoimmunotherapy [32]. Therefore, the hypothesized loss of mitochondrial capacity 122 throughout chemotherapy treatment has not been studied longitudinally starting at baseline and 123 tracking through the chemotherapy regimen in breast and gynecologic cancer patients with NIRS 124 to date.

125 The aims of our study are to develop a protocol that 1) assesses mitochondrial 126 dysfunction in cancer patients using exercise that is tolerable for the patients throughout the 127 entire chemotherapy regimen and 2) explores the link between oxygen utilization at the muscular 128 level via NIRS with whole body traditional metabolic ventilatory measures. This protocol will 129 help us to observe the changes in mitochondrial functional capacity throughout an entire 130 chemotherapy regimen for each patient and between different chemotherapy regimens over time. 131 The protocol also will help us evaluate a potential correlation between subjective self-reported 132 fatigue and perceived effort with corresponding objective metabolic and NIRS

It is made available under a CC-BY 4.0 International license .

measurements. The proposed study will help inform clinical decision makers in the oncology
community regarding current chemotherapy regimens (based upon the National Comprehensive
Cancer Network, NCCN) that patients may best tolerate for cachexia and fatigue.

136

137 Materials and Methods

138

139 Organization and conduct

140 The study protocol (Fig 1) was approved in July of 2021 by the Prisma Health 141 Office of Human Subjects Protection Institutional Review Board Committee C (Protocol # 142 Pro00110826). This study is sponsored through the Prisma Health Cancer Institute Office of 143 Philanthropy and Partnership, the University of South Carolina School of Medicine Greenville 144 Summer Scholars Program, and Furman University. The study sponsors and funders, played no 145 role in study design; collection, management, analysis, and interpretation of data; writing of the 146 report; and the decision to submit the report for publication, including whether they will have 147 ultimate authority over any of these activities. This clinical trial has been registered with 148 clinicaltrials.gov (Identifier: NCT006672497). Data collection started on July 26, 2021 and is 149 ongoing through May 1, 2025.

150

(Insert Figure 1 here)

151 Fig 1. Schedule of Enrollments, Interventions, and Assessments.

It is made available under a CC-BY 4.0 International license .

8

152 **Experimental Design**

153	We will use an observational mixed model repeated measures design to longitudinally
154	compare (pre-chemotherapy and throughout treatment) patients' skeletal muscle mitochondrial
155	capacity of the vastus lateralis during stationary cycling. The study population will include
156	female patients with breast or gynecological cancer. All testing will take place in the University
157	of South Carolina School of Medicine Greenville's Human Performance Laboratory in the
158	Prisma Health Cancer Institute.

159

160 Sample Size

161 We conducted a power analysis using Monte Carlo data simulation. We conducted the 162 analysis using a mixed effects model with a fixed effect of chemotherapy cycle (time) and 163 random effects for slope and intercept by participants with unstructured correlation [33–36]. Due 164 to limited studies of NIRS measurements of patients with cancer, we used the conservative 165 estimate of average recovery kinetics time constant (τ) of patients with chronic heart failure 166 (25.35 seconds) and extrapolate average change in τ throughout chemotherapy from Foulkes 167 using results from Beever [37,38]. We assume that the random intercept will follow a gamma 168 distribution with shape 1.57, a scale of 12.5, and a right shift of 13.25. Additional assumptions 169 from Foulkes [38] and Beever [37] include the random slope is assumed to follow a normal 170 distribution with an extrapolated standard deviation, as well as a normal distribution of the error

171	with standard deviation of 5.54 [39,40]. Analysis indicates that using a linear mixed effects
172	model with sample size of at least n=30 will be able to detect an effect of chemotherapy on τ
173	with a power of 0.8. As the effect of chemotherapy type on τ is unknown and unable to be
174	approximated with data simulation, we are unable to conduct a full power analysis with the effect
175	of chemotherapy type on τ [29,41,42]. We assume that at least n=8 of each chemotherapy type
176	will be necessary to detect any differences in trajectory of τ over time.

177

178 Participants and Eligibility Requirements

179 Participants recruited for this study will be female patients with breast cancer or 180 gynecological cancer who will undergo a standard of care chemotherapy treatment as directed by 181 their oncologist. Participants who are cleared by their oncologist to participate will be recruited 182 through informative pamphlets and by oncology nurses trained in research and human subjects 183 protection in Prisma Health System's Cancer Institute at Greenville Memorial Hospital, as well 184 as Prisma Health affiliated oncologists' offices. Participants will be informed of the study's 185 purpose, availability, timeline, and potentially associated minimal risks. Study staff will then 186 obtain written informed consent from participants who agree to participate and before any data 187 collection.

188 **Table1. Inclusion and Exclusion Criteria**

It is made available under a CC-BY 4.0 International license .

Inclusion Criteria

Female patients diagnosed with breast cancer or gynecological cancer without distant metastasis

Age > 20 years old

Able to perform exercise on a stationary cycle ergometer at moderate intensities for a maximum of 15 minutes

Hemoglobin (Hb) values > 10 g/dl at baseline

Alanine aminotransferase (ALT) and Aspartate transferase (AST) values less than 2.5X the upper limit of normal by institutional standards

Godin-Shephard Leisure Time Physical Activity Questionnaire (GLTEQ) score of 14 or higher

Exclusion Criteria

Metastatic breast or gynecological cancer

It is made available under a CC-BY 4.0 International license .

Clinically advanced cardiovascular disease or pulmonary disease or disease requiring continuous oxygen supplementation

Greater than 2 centimeters of subcutaneous adipose tissue on the anterior thigh

Inability to walk or stand, movement disorders, spinal cord injuries

Autoimmune disorders

Pregnant or breastfeeding

Mini-Mental State Examination (MMSE) score < 24

History of chemotherapy within 5 years prior to beginning participation

189

Observational Protocol for First and Subsequent Visits

Before starting chemotherapy, patients will undergo baseline testing that includes a lactate threshold test and an ON-OFF kinetics exercise test. The lactate threshold test will determine the power output (110% power at lactate threshold, P_{LT+}) to be used for the follow-up baseline on-off kinetics test (ON-OFF). The ON-OFF kinetics test will take place at least 24 hours after the lactate threshold test and consist of 3 cycles of 2 minutes at P_{LT+} and 2 minutes of

196 complete rest. Whole body O₂ uptake and CO₂ production will be captured via a metabolic cart 197 during each test. Testing will take no more than 60 minutes per session, with a maximum study 198 total of 300 minutes (about 5 hours) of participation per patient. Patients will be requested to 199 avoid exercise and use of certain substances (tobacco, alcohol, caffeine, and contraindicated 190 medications) 24 hours before testing. If laboratory baseline evaluation cannot be completed prior 191 to the participant's treatment initiation, treatment will not be delayed, and patients will be waived 202 from the study.

The independent variables in this study are drug regimen and number of chemotherapy treatments. The dependent variables in this study will be the changes in O_2Hb , HHb, and TSI of the vastus lateralis, indicative of mitochondrial oxidative capacity after a bout of cycling. The specific variables measured will be the average recovery kinetics time constant, τ , and TSI. Indirect calorimetry (O2 uptake, CO2 production) also will be captured at rest and during the ON/OFF kinetics as control variable comparisons for whole-body O2 uptake and utilization.

209 Instruments and Equipment

The following devices will be utilized throughout the study: NIRS PortaMon by Artinis
(Einsteinweg, Netherlands), Lode Corival (Groningen, Netherlands) stationary bike ergometer,
Parvo Medics TrueOne 2400 (Salt Lake City, Utah) metabolic cart, Polar FT7 heart rate (HR)
monitor (Kempele, Finland), Lactate Plus analyzer (Edina, Minnesota) and Sonosite Titan
Portable Ultrasound System (Bloomfield, Connecticut) for adipose tissue thickness
measurement.

It is made available under a CC-BY 4.0 International license .

13

Fatigue and Quality of Life Surveys 216

217	We will administer the Mini-Mental State Exam (MMSE) [43-45], Brief Fatigue
218	Inventory (BFI) [46], Physical Activity Intake [47,48], PROMIS Global Health [49,50], and
219	GLTPAQ surveys [51] prior to participant engagement in cycling exercises at the beginning of
220	the first visit. We will administer BFI, PROMIS Global Health, and Physical Activity follow-up
221	surveys at the beginning of each individual study session to assess any changes in cancer related
222	fatigue associated with chemotherapy treatment that may develop throughout the study period.
223	
224	Visit #1: Lactate Threshold Test to Determine Power Output, NIRS
225	Orientation
226	Participants will be asked to wear comfortable exercise clothes with shorts or equivalent
227	so that the NIRS device can be placed directly on the skin. Participants will enter the
228	performance lab and sit at rest in a chair. The NIRS device will be secured to the participant's
220	performance rab and sit at rest in a chair. The NTKS device will be secured to the participant s

230 lateral border of the patella [52]. This distance will be measured and marked medially and

231 laterally on the patient's leg at a place that will not disrupt signal transmission. At this marked

232 location, an ultrasound probe will be used to measure the subcutaneous adipose tissue thickness

- 233 (ATT) between the epidermal layer and the muscular layer. If the ATT meets the
- 234 inclusion/exclusion criteria, the NIRS device will be placed on the vastus lateralis. The
- 235 ultrasound ATT measurement will be recorded. The NIRS device will be secured to the

It is made available under a CC-BY 4.0 International license .

14

236	participant's leg via double-sided non-latex adhesive tape applied between the device and the leg
237	and lightly secured in position to the skin via non-latex tape. Pictures of the anatomical location
238	of NIRS device placement with a tape measure from the center of the anterior border of the
239	patella to the top of the NIRS device will be taken to standardize placement at every visit.
240	The patient will then complete the following questionnaires: contact information form,
241	GLTPAQ, MMSE, BFI, PROMIS, and Physical Activity Form. After the completion of the
242	questionnaires, study staff will review the GLTPAQ and Physical Activity form. Study staff will
243	determine the initial power wattage for the test based on the answers to these surveys.
244	Sitting with both feet on the floor and legs uncrossed, manual blood pressure will be
245	obtained two separate times, five minutes apart after 10 minutes of seated rest. Blood pressure
246	measurements with an average of $<140/<90$ is to be considered safe to continue with testing [20].
247	After the blood pressure measurement is obtained, the patient will have their temperature
248	measured one time and their height and weight measured two times without shoes. The HR
249	monitor will be fitted on the patient to continuously monitor HR throughout exercise. The rate of
250	perceived exertion (RPE) scale will be explained to the patient. The patient will mount the
251	stationary bike and study staff will help adjust the seat, handlebars, and pedals to the comfort of
252	the patient. Study staff will then place a fitted silicone one-way rebreathing mask on the patient
253	to measure their metabolic data using indirect calorimetry via the metabolic cart that captures
254	expired gasses (O ₂ and CO ₂). Capillary blood lactate levels will be obtained by finger stick for the
255	lactate analyzer.

It is made available under a CC-BY 4.0 International license .

15

256	Participants will sit on the stationary bike for two minutes to capture expired gases and
257	blood lactate levels at rest. At the end of rest, the patient will begin pedaling at a self-selected
258	steady cadence between 60 and 100 RPMs at the initial power wattage determined by study staff.
259	The patient will pedal at this cadence for the remainder of the test. Every three minutes, the
260	power output will increase by 15 Watts. With thirty seconds remaining in each stage, blood
261	lactate levels will be measured in duplicate and study staff will prompt the participant to quantify
262	their effort using the RPE scale. When the duplicate blood lactate measurements exceed 4.0
263	mmol/L, the participant will complete the current stage and end the test.
264	After completion of the test, study staff will calculate the power output that is equivalent
265	to 1.1x the wattage at which patients' lactate exceeded 4.0 mmol/L (P_{LT+}). This power output
266	will be used as the exercise intensity for subsequent on-off kinetics testing.
267	
268	Visit #2+: On-Off Kinetics Testing
2(0)	

Using the reference photo taken at the first visit, mark the NIRS device location and use the ultrasound to measure and record ATT. If the ATT measurement matches the ATT from the first visit, secure the NIRS device with tape as previously described. The participant will fill out the BFI, PROMIS Global Health, and Physical Activity Follow Up forms and update contact information if needed.

The participants will sit on the bike for a two-minute rest. Participants will begin
pedaling for a warmup at 0 Watts for 2 minutes at a self-selected steady cadence of 60-100 RPM.

It is made available under a CC-BY 4.0 International license .

16

276 After the 2-minute warm up, the power output will increase to P_{LT+}. Participants will cycle at the 277 same self-selected cadence for 2 minutes ("on-kinetics"). Thirty seconds before the end of the 278 on-kinetics stage, participants will be asked their RPE. At the end of the 2-minute on-kinetics 279 period, participants will stop pedaling and study staff will remove their non-measured leg from 280 the pedal to rest on a box in a relaxed, extended position to aid in total relaxation and remove any 281 additional movement of the measured leg. During the rest period, participants will remain in 282 recovery sitting on the bike for 2 minutes ("off-kinetics" stage). Participants subsequently will 283 start pedaling at their self-selected cadence for their next 2 minute "on-kinetics" stage, followed 284 by another 2-min "off-kinetics" period. This cycle of exercise followed by rest, referred to as on-285 off kinetics, will repeat for a total maximum of 3 times, or unless the patient requests to stop.

286

287 **Outcome measures**

288 Collection of biometrics at each visit

Study staff will measure O2Hb, HHb, and TSI, via the NIRS PortaMon device during the on-off kinetics protocol. We also will measure ventilatory whole-body components including O_2 and CO_2 via the Parvomedics metabolic cart. Participants' perceived exertion to the exercise will be measured via RPE during every exercise stage.

- 293 NIRS data will be collected using Artinis Medical System's Oxysoft software at a
- frequency of 10hz. A differential pathlength factor (DPF) value of 4 will be selected, as
- recommended by Artinis (Einsteinweg, Netherlands). The PortaMon will be placed on the vastus

It is made available under a CC-BY 4.0 International license .

296	lateralis of participants for a period of at least 10 minutes prior to beginning exercise in
297	accordance with the recommendation of Cortese L, et al. to allow calibration of the PortaMon
298	[53].

Throughout data collection, researchers will closely observe for excess movement from
participants that may affect the data collection. These sections will be removed from analysis.
After data collection, a moving average with a filter width of 1.5 seconds will be applied to
smooth leg movement artifacts that occurred during cycling. Data cleaning and analysis will be
conducted using R (R Core Team, 2020) and RStudio (Rstudio Team, 2020).

304

305 Data analysis and Statistical analysis

306 Previous literature has shown that oxygenation levels at rest after moderate and/or high
307 intensity exercise or after occlusion follows an asymptotic curve of the form [54]:

308

309
$$y = A + (B_0 - A) e^{-\tau/t}$$
 (2)

310

311 Where *y* is the oxygenation at time *t*, *A* is the oxygenation as *t* approaches infinity, *t* is 312 time measured in seconds, B_{θ} is the value at t=0, and τ is the time constant. For each rest period, 313 we will run an asymptotic regression for O2Hb, HHb, and TSI by time in seconds to find the 314 coefficient estimate for τ .

It is made available under a CC-BY 4.0 International license .

18

315	Each data set will contain three rest periods; therefore, each data set will have three τ
316	values for each variable. We will average the τ values to obtain one average rest τ for O ₂ Hb,
317	HHb, and TSI per data set. Since continuous wave NIRS devices measure oxy- and
318	deoxyhemoglobin as changes from baseline, raw oxy- and deoxyhemoglobin values will have no
319	meaning and are not comparable except when measured as changes over time or as τ values.

320 We will analyze the ΔO_2Hb , ΔHHb , and ΔTSI , calculated as the change in steady state 321 levels of O₂Hb, HHb, and TSI respectively from work to rest, with steady state values calculated 322 as the mean value of the final thirty seconds of the stage. For each data set of one on-off kinetics, 323 there will be three work/rest period pairs therefore we will calculate three delta values and 324 average the three delta values to obtain one delta value for O₂Hb, HHb, and TSI per data set. The 325 three work/rest transitions will allow for reliability testing with intraclass correlation coefficients. 326 For participant data to be included in the final analysis, the participant will need to complete at 327 least three on-off kinetic laboratory visits. Each participant will complete an on-off kinetics at 328 least two weeks apart, but not more than one month apart in accordance with their prescribed 329 chemotherapy treatment regimen. Each on-off kinetics will correspond with the first infusion of a 330 chemotherapy cycle. To allow participants a maximum amount of time to recover from infusions 331 before participating in exercise, the corresponding on-off kinetics takes place within 48 hours of 332 the first infusion of the subsequent chemotherapy cycle. Since chemotherapy treatments vary 333 depending on oncologist recommendation, each participant may complete different lengths of 334 treatment, resulting in each participant having different numbers of data points. This will prevent 335 us from using traditional statistical analysis such as repeated measures ANOVA. Since it is not 336 time itself, but rather the compilation of chemotherapy infusions over time that we predict will

It is made available under a CC-BY 4.0 International license .

337	cause changes in measures of mitochondrial oxidative function, we will treat the number of
338	chemotherapy cycles as an ordinal variable in this analysis. We will complete an analysis using
339	mixed effects models to predict τ and deltas from the number of chemotherapy treatments with a
340	random intercept for patients.

341

342 Data Management Plan

Patient health information (PHI) will be obtained directly from the patient and the
electronic medical record (EMR). This information will only be obtained after documented
informed consent has been provided by the patient. PHI will be stored in the Prisma Health
RedCap[®], a HIPAA compliant cloud platform. All data will be housed within the Prisma Health
system. Surveys and questionnaires will be stored in a locked file cabinet in a locked room in the
Human Performance Laboratory.

349

350 Trial Oversight

This study has been approved by the Institutional Review Board at the Prisma Office of Research Compliance and Administration (ORCA). All adverse events (AE) and serious adverse events (SAE) will be recorded from the start of the visits, beginning with the first visit for lactate threshold testing and throughout completion of exercise visits, or when the participant has elected to no longer participate. The investigators will record and report all AE and SAE to the

It is made available under a CC-BY 4.0 International license .

20

356 IRB within 24 hours. Fatal or life threatening unexpected adverse reactions will be reported to357 Prisma Health IRB immediately.

358

359 **Discussion**

360 With limited studies of mitochondrial function (e.g. oxygen delivery and utilization) 361 during cancer chemotherapy, opportunity exists to address mechanisms of cachexia and cancerrelated fatigue using NIRS. To date, two main studies used NIRS with cancer populations. 362 363 However, neither of the research teams collected data during active chemotherapy treatment, and 364 they only measured steady-state values during exercise as opposed to collecting oxygen kinetics 365 during recovery and exercise. Additionally, the independent variables included treatments 366 additional to chemotherapy, including radiation and immunotherapy. The variation in 367 independent variables may have been the reason for limited changes in the NIRS outcome 368 variables. Ederer, et al [29] found significant differences in HHb and total hemoglobin with a 369 limited sample size of 8 cancer survivors compared to matched controls, while Grigoriadis et al. 370 [30] found no significant differences in any of the NIRS variables. Understanding oxygen 371 delivery and utilization kinetics with ventilatory and local NIRS measurements during 372 chemotherapy could unlock mechanistic understanding of mitochondrial dysfunction. Our study 373 will be the first to recruit at least 30 patients diagnosed with cancer and capture both baseline and 374 longitudinal NIRS measurements throughout the entire chemotherapy protocol.

It is made available under a CC-BY 4.0 International license .

21

375 The study's design must consider 1) exercise tolerance levels to obtain fatigue and 376 recovery kinetics for patients going through chemotherapy and 2) rapid recruitment of patients 377 for baseline measurements. We recognize that the level of conditioning our patients have at 378 baseline may be reduced as treatment progresses. Therefore, we chose a protocol that was 379 tolerable to patients, which is to cycle to 10% above their lactate threshold level; both before 380 discontinuing the LT test and for the on/off kinetics tests. This intensity elicits an appropriate 381 mitochondrial response in the exercising muscle while allowing for a reasonable exercise 382 intensity that a patient can complete despite anticipated treatment deconditioning. Additionally, 383 because patient recruitment will occur at the time of diagnosis, a team of referral coordinators, 384 nurse navigators, and oncologists need to identify newly diagnosed patients, and be prepared, 385 through a "chemo-teach", to consent interested patients in a timely manner.

386 A few limitations are to be considered regarding the validity of the PortaMon by Artinis 387 Medical Systems. First, the device is designed to accurately penetrate 20 mm of depth through 388 adipose tissue and into the muscle belly. If the subcutaneous adipose tissue thickness is greater 389 than 20 mm, the infrared signal from the device will not penetrate the skeletal muscle body and 390 be unable to obtain accurate measurements. Our protocol minimizes this concern by excluding 391 participants who have greater than 20 mm adipose tissue subcutaneous to the vastus lateralis, and 392 by standardizing device placement on the leg from test to test to increase reliability and validity 393 of repeated measures measurements. Ambient light can interfere with the signal quality, however 394 Oxysoft provides real-time data acquisition (DAQ) measurements. Using the manufacturer's 395 recommendation, channels with DAQ higher than 97% will be removed from analysis.

396	Results from this pilot study will provide information on the feasibility of capturing
397	on/off kinetics mitochondrial function data longitudinally using NIRS in patients newly
398	diagnosed with breast or gynecological cancer, provide preliminary data for future extramural
399	funding, and inform the scientific community of results through dissemination via conference
400	presentations and peer-reviewed publications.

401 **References**

402 403 404	1.	DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67: 439–448. doi:10.3322/caac.21412
405	2.	National Cancer Institute. Cancer Stat Facts: Ovarian Cancer. 23 Sep 2023.
406	3.	American Society of Clinical Oncology. Uterine Cancer - Statistics. 26 Mar 2023.
407 408 409 410	4.	Freedman RJH, Aziz N, Albanes D, Hartman T, Danforth D, Hill S, et al. Weight and Body Composition Changes during and after Adjuvant Chemotherapy in Women with Breast Cancer. J Clin Endocrinol Metab. 2004;89: 2248–2253. doi:10.1210/jc.2003- 031874
411 412 413	5.	Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, et al. Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition. Oncologist. 2000;5. doi:10.1634/theoncologist.5-5-353
414 415 416 417	6.	Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. Journal of Clinical Oncology. 2004;22. doi:10.1200/JCO.2004.03.516
418 419 420	7.	Kayl AE, Meyers CA. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Current Opinion in Obstetrics and Gynecology. 2006. doi:10.1097/01.gco.0000192996.20040.24
421 422	8.	National Cancer Institute. Treating Cancer Cachexia: Progress Looks Possible. 2022. Available: https://www.cancer.gov/about-cancer/treatment/research/cachexia

423 424 425	9.	Amano K, Baracos VE, Morita T, Miura T, Mori N, Tatara R, et al. The impact of cachexia on dietary intakes, symptoms, and quality of life in advanced cancer. JCSM Rapid Commun. 2022;5: 162–170. doi:10.1002/rco2.61
426 427 428	10.	Beltrà ME, Pin F, Ballarò R, Costelli P, Penna F. Mitochondrial Dysfunction in Cancer Cachexia: Impact on Muscle Health and Regeneration. Cells. 2021;10: 3150. doi:10.3390/cells10113150
429 430 431	11.	Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. NCCN guidelines insights: breast cancer, version 1.2017. Journal of the National Comprehensive Cancer Network. 2017;15: 433–451.
432 433 434 435	12.	Bohlen J, McLaughlin SL, Hazard-Jenkins H, Infante AM, Montgomery C, Davis M, et al. Dysregulation of metabolic-associated pathways in muscle of breast cancer patients: preclinical evaluation of interleukin-15 targeting fatigue. J Cachexia Sarcopenia Muscle. 2018;9. doi:10.1002/jcsm.12294
436 437 438	13.	Wilson HE, Stanton DA, Rellick S, Geldenhuys W, Pistilli EE. Breast cancer-associated skeletal muscle mitochondrial dysfunction and lipid accumulation is reversed by PPARG. Am J Physiol Cell Physiol. 2021;320. doi:10.1152/ajpcell.00264.2020
439 440 441	14.	Guigni BA, Callahan DM, Tourville TW, Miller MS, Fiske B, Voigt T, et al. Skeletal muscle atrophy and dysfunction in breast cancer patients: Role for chemotherapy-derived oxidant stress. Am J Physiol Cell Physiol. 2018;315. doi:10.1152/ajpcell.00002.2018
442 443 444	15.	Patterson MS, Chance B, Wilson BC. Time resolved reflectance and transmittance for the non-invasive measurement of tissue optical properties. Appl Opt. 1989;28: 2331–2336. doi:10.1364/ao.28.002331
445 446 447	16.	Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol. 2015;77: 753–759. doi:10.1002/ana.24362
448 449 450 451	17.	Chung S, Rosenberry R, Ryan TE, Munson M, Dombrowsky T, Park S, et al. Near-infrared spectroscopy detects age-related differences in skeletal muscle oxidative function: promising implications for geroscience. Physiol Rep. 2018;6: e13588-n/a. doi:10.14814/phy2.13588
452 453 454	18.	Jones LW, Eves ND, Haykowsky M, Freedland SJ, Mackey JR. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. The Lancet Oncology. 2009. pp. 598–605. doi:10.1016/S1470-2045(09)70031-2

455 456 457	19.	Jones LW, Eves ND, Mackey JR, Peddle CJ, Haykowsky M, Joy AA, et al. Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung Cancer. 2007;55: 225–232. doi:10.1016/j.lungcan.2006.10.006
458 459 460	20.	Sietsema KE, Stringer WW, Sue DY, Ward S. Wasserman & Whipp's: Principles of Exercise Testing and Interpretation: Including Pathophysiology and Clinical Applications. 6th ed. Zinner S, editor. Philadelphia, PA: Lippincott Williams & Wilkins; 2020.
461 462 463	21.	Peel AB, Thomas SM, Dittus K, Jones LW, Lakoski SG. Cardiorespiratory fitness in breast cancer patients: a call for normative values. Journal of the American Heart Association. 2014. doi:10.1161/JAHA.113.000432
464 465 466	22.	Ghatas MP, Holman ME, Gorgey AS. Methodological considerations for near-infrared spectroscopy to assess mitochondrial capacity after spinal cord injury. J Spinal Cord Med. 2020;43: 623–632. doi:10.1080/10790268.2019.1631585
467 468 469	23.	Van Beekvelt MCP, Colier WNJM, Wevers RA, Van Engelen BGM. Performance of near-infrared spectroscopy in measuring local O2 consumption and blood flow in skeletal muscle. J Appl Physiol. 2001;90: 511–519. doi:10.1152/jappl.2001.90.2.511
470 471 472 473	24.	Wilkinson TJ, White AEM, Nixon DGD, Gould DW, Watson EL, Smith AC. Characterising skeletal muscle haemoglobin saturation during exercise using near-infrared spectroscopy in chronic kidney disease. Clin Exp Nephrol. 2019;23: 32–42. doi:10.1007/s10157-018-1612-0
474 475 476	25.	Willingham TB, McCully KK. In Vivo Assessment of Mitochondrial Dysfunction in Clinical Populations Using Near-Infrared Spectroscopy. Front Physiol. 2017;8. doi:10.3389/fphys.2017.00689
477 478 479	26.	Cuartas-Vélez C, Veenstra C, Kruitwagen S, Petersen W, Bosschaart N. Optical density based quantification of total haemoglobin concentrations with spectroscopic optical coherence tomography. Sci Rep. 2021;11: 8680. doi:10.1038/s41598-021-88063-4
480 481 482 483	27.	Baker WB, Li Z, Schenkel SS, Chandra M, Busch DR, Englund EK, et al. Effects of exercise training on calf muscle oxygen extraction and blood flow in patients with peripheral artery disease. J Appl Physiol. 2017;123: 1599–1609. doi:10.1152/japplphysiol.00585.2017
484 485 486 487	28.	Brochhagen J, Coll Barroso MT, Baumgart C, Freiwald J, Hoppe MW. Non-invasively measured central and peripheral factors of oxygen uptake differ between patients with chronic heart failure and healthy controls. BMC Cardiovasc Disord. 2020;20: 378. doi:10.1186/s12872-020-01661-4

488 489 490	29.	Ederer AK, Didier KD, Reiter LK, Brown M, Hardy R, Caldwell J, et al. Influence of Adjuvant Therapy in Cancer Survivors on Endothelial Function and Skeletal Muscle Deoxygenation. PLoS One. 2016;11: e0147691. doi:10.1371/journal.pone.0147691
491 492 493 494	30.	Grigoriadis G, Sherman SR, Lima NS, Lefferts EC, Hibner BA, Ozemek HC, et al. Breast cancer survivors with preserved or rescued cardiorespiratory fitness have similar cardiac, pulmonary and muscle function compared to controls. Eur J Appl Physiol. 2022. doi:10.1007/s00421-022-04992-6
495 496 497 498	31.	Vitorino R, Barros AS, Guedes S, Caixeta DC, Sabino-Silva R. Diagnostic and monitoring applications using near infrared (NIR) spectroscopy in cancer and other diseases. Photodiagnosis and Photodynamic Therapy. Elsevier B.V.; 2023. doi:10.1016/j.pdpdt.2023.103633
499 500 501	32.	Wakiyama H, Kato T, Furusawa A, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy of cancer; Possible clinical applications. Nanophotonics. De Gruyter Open Ltd; 2021. pp. 3135–3151. doi:10.1515/nanoph-2021-0119
502 503 504	33.	DeBruine LM, Barr DJ. Understanding Mixed-Effects Models Through Data Simulation. Adv Methods Pract Psychol Sci. 2021;4: 251524592096511. doi:10.1177/2515245920965119
505 506 507	34.	Cheng J, Edwards LJ, Maldonado-Molina MM, Komro KA, Muller KE. Real longitudinal data analysis for real people: Building a good enough mixed model. Stat Med. 2010;29: 504–520. doi:10.1002/sim.3775
508 509 510	35.	Guo Y, Logan HL, Glueck DH, Muller KE. Selecting a sample size for studies with repeated measures. BMC Med Res Methodol. 2013;13: 100. doi:10.1186/1471-2288-13-100
511 512 513	36.	Kumle L, Võ ML-H, Draschkow D. Estimating power in (generalized) linear mixed models: An open introduction and tutorial in R. Behav Res Methods. 2021;53: 2528–2543. doi:10.3758/s13428-021-01546-0
514 515 516	37.	Beever AT, Tripp TR, Zhang J, MacInnis MJ. NIRS-derived skeletal muscle oxidative capacity is correlated with aerobic fitness and independent of sex. Journal of applied physiology (1985). 2020;129: 558–568. doi:10.1152/japplphysiol.00017.2020
517 518 519	38.	Foulkes S, Howden E, Bigaran A, Janssens K, Antill Y, Loi S, et al. Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy. Med Sci Sports Exerc. 2019;51: 1573–1581. doi:10.1249/MSS.000000000001970

520	39.	Niemeijer VM, Jansen JP, van Dijk T, Spee RF, Meijer EJ, Kemps HMC, et al. The
521		influence of adipose tissue on spatially resolved near-infrared spectroscopy derived
522		skeletal muscle oxygenation: the extent of the problem. Physiol Meas. 2017;38: 539–554.
523		doi:10.1088/1361-6579/aa5dd5

- 40. Niemeijer VM, Spee RF, Schoots T, Wijn PFF, Kemps HMC. Limitations of skeletal
 muscle oxygen delivery and utilization during moderate-intensity exercise in moderately
 impaired patients with chronic heart failure. Am J Physiol Heart Circ Physiol. 2016;311:
 H1530–H1539. doi:10.1152/ajpheart.00474.2016
- Jenkins DG, Quintana-Ascencio PF. A solution to minimum sample size for regressions.
 PLoS One. 2020;15: e0229345. doi:10.1371/journal.pone.0229345
- van Hooff M, Meijer EJ, Scheltinga MRM, Savelberg HHCM, Schep G. Test-retest
 reliability of skeletal muscle oxygenation measurement using near-infrared spectroscopy
 during exercise in patients with sport-related iliac artery flow limitation. Clin Physiol
 Funct Imaging. 2022;42: 114–126. doi:10.1111/cpf.12738
- Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for
 grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12: 189–198.
 doi:10.1016/0022-3956(75)90026-6
- 537 44. Foreman MD, Fletcher K, Mion LC, Simon L. Assessing cognitive function. Geriatr Nurs.
 538 1996;17: 228–32; quiz 233. doi:10.1016/s0197-4572(96)80210-2
- 539 45. Foreman MD, Grabowski R. Diagnostic Dilemma: Cognitive Impairment in the Elderly. J
 540 Gerontol Nurs. 1992;18: 5–9. doi:10.3928/0098-9134-19920901-04
- 46. Mendoza T, Wang X, Cleeland C, Morrissey M, Johnson B, Wendt J, et al. The rapid
 assessment of Fatigue severity in cancer patients: Use of the Brief Fatigue Inventory.
 Cancer. 1999;85: 1186–1196. doi:10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-
 CNCR24>3.0.CO;2-N
- 545 47. Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, Minson CT, Nigg CR, Salem GJ,
 546 et al. Exercise and Physical Activity for Older Adults. Med Sci Sports Exerc. 2009;41:
 547 1510–1530. doi:10.1249/MSS.0b013e3181a0c95c
- 548 48. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al.
 549 Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory,
 550 Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults. Med Sci Sports
 551 Exerc. 2011;43: 1334–1359. doi:10.1249/MSS.0b013e318213fefb

552 553 554	49.	Lam KH, Kwa VIH. Validity of the PROMIS-10 Global Health assessed by telephone and on paper in minor stroke and transient ischaemic attack in the Netherlands. BMJ Open. 2018;8: e019919. doi:10.1136/bmjopen-2017-019919
555 556 557	50.	Katzan IL, Lapin B. PROMIS GH (Patient-Reported Outcomes Measurement Information System Global Health) Scale in Stroke: A Validation Study. Stroke (1970). 2018;49: 147– 154. doi:10.1161/STROKEAHA.117.018766
558 559 560 561	51.	Amireault S, Godin G, Lacombe J, Sabiston CM. Validation of the Godin-Shephard Leisure-Time Physical Activity Questionnaire classification coding system using accelerometer assessment among breast cancer survivors. Journal of cancer survivorship. 2015;9: 532–540. doi:10.1007/s11764-015-0430-6
562 563 564 565 566	52.	Bergstrom HC, Housh TJ, Dinyer TK, Byrd TM, Jenkins NDM, Cochrane-Snyman KC, et al. Neuromuscular responses of the superficial quadriceps femoris muscles: muscle specific fatigue and inter-individual variability during severe intensity treadmill running. J Musculoskelet Neuronal Interact. 2000;20: 77–87. Available: https://www.ncbi.nlm.nih.gov/pubmed/32131371
567 568 569 570	53.	Cortese L, Zanoletti M, Karadeniz U, Pagliazzi M, Yaqub MA, Busch DR, et al. Performance Assessment of a Commercial Continuous-Wave Near-Infrared Spectroscopy Tissue Oximeter for Suitability for Use in an International, Multi-Center Clinical Trial. Sensors (Basel). 2021;21: 6957. doi:10.3390/s21216957
571 572 573	54.	Grassi B, Pogliaghi S, Rampichini S, Quaresima V, Ferrari M, Marconi C, et al. Muscle oxygenation and pulmonary gas exchange kinetics during cycling exercise on-transitions in humans. J Appl Physiol. 2003;95: 149–158. doi:10.1152/japplphysiol.00695.2002
574		
575		
576		<u>Trial Status</u>
577		The trial is currently in the data collection phase with 13 participants who have
578	comp	pleted the protocol. The study is planned to continue to enroll test subjects until $n = 30$.
579		

It is made available under a CC-BY 4.0 International license .

28

Author Contributions

- 581 Randy Hutchison: Co-Principal Investigator, NIRS expert, concept for research design and data
- 582 analysis plan, contributory writer
- 583 Shannon Smith: Medical student researcher, supported investigator-led study design through
- 584 performing literature review, assisted in pilot data collection, contributory writer
- 585 Chloe Caudell: Medical student researcher, supported investigator-led study design through
- 586 performing literature review, assisted in pilot data collection, contributory writer
- 587 Sara Biddle: Data analyst, writer, researcher, contributory writer
- 588 W. Larry Gluck, MD: Co-Investigator, medical director of Prisma Health Cancer Institute,
- 589 primary clinical contribution and oversight, contributed to conceptual study design for
- 590 chemotherapy-related fatigue and mitochondrial dysfunction in patients with cancer.
- 591 Jennifer Trilk (corresponding author): Co-Principal Investigator, co-concept for research design
- and data analysis plan, co-author

	Study Period						
	Enrollment		Post Allocation				Close-out
TIMEPOINT**	-t1 (with Oncology Research Nurse)	t1 (Lactate Threshold Baseline Testing in Human Performance Lab)	t2 (baseline on- off kinetics test, pre- chemotherapy cycle 1)	t3 (pre- chemothe rapy cycle 2)	t4 pre- chemotherapy cycle 3)	Etc. until chemotherapy cycles complete	Post Test
ENROLLMENT:							
Eligibility screen	x						
Informed Consent	x						
-see inclusion/exclusion criteria (Table 1)	x						
 -feasibility: capable, willing to participate 	x						
-Godin Leisure Survey		x					
-Ultrasound for adipose tissue thickness		x					
-Mini Mental State Exam		x					
Allocation (N/A, no intervention, observational trial only)							

INTERVENTIONS: Observational study, no interventions, gathering assessments throughout chemotherapy based on oncology prescribed, chemotherapy standard of practice

ASSESSMENTS:						
[Baseline variables]						
Global Heath Promis						
Survey	x	х	х	x	x	х

Figure 1A Schedule Enrollments

Brief Fatigue						
Inventory	x	х	x	x	x	x
Physical Activity	x	х	х	x	x	x
[Outcome variables]						
NIRS Data (O2Hb,						
HHb, TSI, τ, etc.)	x	х	x	x	x	x
Ventilatory						
Metabolic						
Measurements (VO2,						
VCO2, etc.)	x	x	x	x	x	x
Heart Rate	x	х	x	x	x	x
Rate of Perceived						
Exertion	x	x	x	x	x	x
[Other data						
variables]						
Height	x	x	х	x	x	х
Weight	x	х	х	x	x	х
Blood Pressure	x	x	х	x	x	х
Temperature	x	x	x	x	x	x
Ultrasound for	x	x	x	x	x	x
adipose tissue						
thickness						

Fig 1. Schedule of Enrollments, Interventions, and Assessments.

Figure 1B Schedule Enrollments